NCT04604548 - The KHENEREXT Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions

Mitochondrial DiseasesMitochondrial DNA tRNALeu(UUR) m.3243A<G MutationMaternally Inherited Diabetes and Deafness (MIDD)Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS)Chronic Progressive External Ophthalmoplegia (CPEO)

Interventions

DRUG

Oral administration of 100 mg KH176 twice daily

Drug: KH176

Trial Locations (4)

80336

Klinikum der Universität München Friedrich-Baur-Institut, München

DK2100

Rigshospitalet, University of Copenhagen, Copenhagen

Unknown

Radboud University Medical Center, Nijmegen

Institute for Ageing and Health Newcastle University, Newcastle upon Tyne